Matthew R. Meyer

The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers

David A. Russler‐Germain, David H. Spencer, Margaret A. Young et al. · Cancer Cell · 2014 · 449 citations · Full text

Cell Regulation, Aml Dominantly, Genetic Disorder +10

Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays

Andrew N. Hoofnagle, Jeffrey R. Whiteaker, Steven A. Carr et al. · Clinical Chemistry · 2015 · 222 citations · Full text

Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Inge M.W. Verberk, Els O. Misdorp, Jannet Koelewijn et al. · Alzheimer s & Dementia · 2021 · 222 citations · Full text

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Tim West, Kristopher M. Kirmess, Matthew R. Meyer et al. · Molecular Neurodegeneration · 2021 · 220 citations · Full text

Genomic impact of transient low-dose decitabine treatment on primary AML cells

Jeffery M. Klco, David H. Spencer, Tamara Lamprecht et al. · Blood · 2013 · 202 citations